Imatinib (Gleevec)

Indications

  • Chronic Myeloid Leukemia (CML) (see Chronic Myeloid Leukemia, [[Chronic Myeloid Leukemia]])
  • Dermatofibrosarcoma Protuberans
  • Gastrointestinal Stromal Tumors (GIST)

Pharmacology

  • Tyrosine Kinase Inhibitor: epidemal growth factor receptor (EGFR) antagonist

Administration

  • PO

Adverse Effects

Cardiology Adverse Effects

  • Chest Pain (see Chest Pain, [[Chest Pain]]): occurs in >10% of cases
  • Hypotension (see Hypotension, [[Hypotension]]): occurs in >10% of cases (reported cases have been pediatric Philadelphia chromosome-positive ALL cases)
  • Pericardial Effusion (see Pericardial Effusion, [[Pericardial Effusion]]): occurs in >10% of cases
  • Peripheral Edema (see Peripheral Edema, [[Peripheral Edema]]): occurs in >10% of cases

Dermatologic Adverse Effects

  • Dermatitis: occurs in >10% of cases
  • Eczema: occurs in >10% of cases
  • Facial/Periorbital Edema: occurs in >10% of cases
  • Rash: occurs in >10% of cases

Gastrointestinal Adverse Effects

  • Abdominal Pain (see Abdominal Pain, [[Abdominal Pain]]): occurs in >10% of cases
  • Ascites (see Ascites, [[Ascites]]): occurs in >10% of cases
  • Diarrhea (see Diarrhea, [[Diarrhea]]): occurs in >10% of cases
  • Dyspepsia (see Dyspepsia, [[Dyspepsia]]): occurs in >10% of cases
  • Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]]): occurs in >10% of cases
  • Weight Gain (see Weight Gain, [[Weight Gain]]): occurs in >10% of cases

Hematologic Adverse Effects

  • Hemorrhage: occurs in 3-53% of cases
  • Myelosuppression: occurs in >10% of cases
    • Anemia: occurs in 25-80% of cases
    • Leukopenia: occurs in 5-47% of cases
    • Neutropenia: occurs in 12-16% of cases
    • Thrombocytopenia: occurs in 1-31% of cases

Neurologic Adverse Effects

  • Anxiety (see Anxiety, [[Anxiety]]): occurs in 8-12% of cases
  • Depression (see Depression, [[Depression]]): occurs in <15% of cases
  • Dizziness (see Dizziness, [[Dizziness]]): occurs in 5% to 19% of cases
  • Fatigue (see Fatigue, [[Fatigue]]): occurs in >10% (29-75%) of cases
  • Headache (see Headache, [[Headache]]): occurs in >10% (8-35%) of cases
  • Insomnia (see Insomnia, [[Insomnia]]): occurs in 10-15% of cases
  • Parasthesias (see Parasthesias, [[Parasthesias]]): occurs in <12% of cases

Otolaryngologic Adverse Effects

  • Pharyngitis/Laryngitis (see Pharyngitis, [[Pharyngitis]]): occurs in >10% cases
  • Rhinitis (see Rhinitis, [[Rhinitis]]): occurs in >10% cases
  • Sinusitis (see Acute Rhinosinusitis, [[Acute Rhinosinusitis]]): occurs in 4% to 11% of cases
  • Upper Respiratory Tract Infection: occurs in 3% to 21% of cases

Pulmonary Adverse Effects

Rheumatologic/Orthopedic Adverse Effects

  • Bone Pain: occurs in >10% of cases
  • Joint Pain: occurs in >10% of cases
  • Muscle Spasms/Cramps: occurs in >10% of cases
  • Myalgias (see Myalgias, [[Myalgias]]): occurs in >10% of cases

Other Adverse Effects

  • Chills: occurs in <11% of cases
  • Fever (see Fever, [[Fever]]): occurs in 6% to 41% of cases
  • Flu-Like Symptoms: occurs in 1% to 14% of cases
  • Rigors: occurs in 10-12% of cases
  • xxx
  • xxx

References

  • Gleevec (imatinib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. Retrieved 24 January 2014
  • GLEEVEC (imatinib mesylate) tablet [Novartis Pharmaceuticals Corporation]. DailyMed. Novartis Pharmaceuticals Corporation. October 2013. Retrieved 24 January 2014
  • GLIVEC Tablets – Summary of Product Characteristics (SPC). electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd
  • GLIVEC (imatinib) (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Ltd. 21 August 2013. Retrieved 24 January 2014.
  • Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3